Title of article
Immunocheckpoint Inhibitor- (Nivolumab-) AssociatedHypereosinophilia in Non-Small-Cell Lung Carcinoma
Author/Authors
Singh, Navdeep Medicine/Division of Hospice/Palliative Care - North Shore University Hospital - Community Dr. - Manhasset - NY , USA , Lubana, Sandeep Singh Medicine/Division of Hematology/Oncology - SUNY Downstate Medical School - Brooklyn - NY , USA , Constantinou, George Lafayette General Medical Center - Lafayette - LA , USA , Leaf , Andrea N. Medicine/Division of Hematology/Oncology - Brooklyn VA Medical Center - Brooklyn - NY , USA
Pages
5
From page
1
To page
5
Abstract
mmunocheckpoint inhibitor (ICI) therapy has provided significant clinical improvements in the treatment of severalmalignancies. The purpose of this report is to increase awareness of hypereosinophilia associated with checkpoint inhibitors, atopic that has been rarely reported. Hypereosinophilia may need to be addressed especially if eosinophil counts increase to levelswhere hypereosinophilic visceral complications can occur. We are presenting a case of a 57-year-old male withhypereosinophilia that was seen in the setting of progression of metastatic non-small-cell lung cancer during and afternivolumab treatment.
Keywords
Immunocheckpoint Inhibitor - (Nivolumab-) , Associated Hypereosinophilia , Non-Small-Cell Lung Carcinoma , ICI
Journal title
Case Reports in Oncological Medicine
Serial Year
2020
Record number
2609865
Link To Document